HK Stock Market Move | GIANT BIOGENE (02367) surges over 8% in intraday trading, the world's first approved injection of recombinant collagen protein and sodium hyaluronate complex solution.

GIANT BIOGENE (02367) rose over 8% intraday, up 7.03% at the time of publication, trading at HK$34.4 with a turnover of HK$256 million. In terms of news, GIANT BIOGENE recently announced that its three types of medical devices, including "recombinant type I alpha 1 subtype collagen and sodium hyaluronate composite solution", have been approved. This product is the world's first recombinant collagen and hyaluronic acid composite solution implant product for improving smoothness of the cheeks, which has officially been approved through a joint review of medical device and drug approvals. Zhongjin said that it is optimistic about the approval of this product to further expand the medical beauty product matrix, confirming the company's leading technology research and development capabilities. Looking ahead in the medium to long term, the firm believes that the company's research and development capabilities, brand awareness, and team cohesion are still solid. With the improvement in the cosmetics market and increased contributions from medical beauty, it is recommended to pay attention to opportunities for positioning.